Lysophosphatidic Acid in Ovarian Cancer Patients

Authors: I. Sedláková 1;  J. Vávrová 2;  J. Tošner 1;  L. Hanousek 3
Authors‘ workplace: Gynekologicko-porodnická klinika LF UK a FN Hradec Králové, přednosta doc. MUDr. J. Tošner, CSc. 1;  Ústav klinické biochemie a diagnostiky FN Hradec Králové, přednosta prof. MUDr. V. Palička, CSc. 2;  Gynekologicko-porodnické oddělení, Krajská nemocnice Pardubice, primář MUDr. L. Hanousek, CSc. 3
Published in: Čes. Gynek.2006, 71, č. 4 s. 312-317
Category: Original Article


To compare plasma lysophosphatidic acid (LPA) level in ovarian cancer patients and women without ovarian pathology.

Prospective study.

Department of Gynecology and Obstetrics, University Hospital, Hradec Králové.

The method for LPA level analyze with its specification by capillary electrophoresis using indirect ultraviolet detection has been implementated. Since the beginning of this project venous blood samples from 103 patients (60 patients with ovarian cancer, 43 patients without ovarian pathology) have been obtained.

Plasma LPA levels were elevated in ovarian cancer patients (Σ LPA Med 19.9 μmol/l, Range 4.5 – 42.7 μmol/l). Patients without ovarian pathology (n=35) (Σ LPA Med 2.6 μmol/l, Range 0.9 – 22.9 μmol/l, P<0,001) had statistically significant lower plasma LPA level compared with ovarian cancer patients.

Lysophosphatidic acid appears useful as diagnostic marker of ovarian cancer.

Key words:
ovarian cancer, lysophosphatidic acid, marker

Paediatric gynaecology Gynaecology and obstetrics Reproduction medicine

Article was published in

Czech Gynaecology

Issue 4

2006 Issue 4

Most read in this issue

This topic is also in:

Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account